A comprehensive view of Bluebird Bio Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Bluebird bio secures first Medicaid outcomes-based agreement with state of Michigan for its gene therapy Lyfgenia lovo-cel for sickle cell disease; Bluebird is in discussions with 15 other agencies
Published: March 12, 2024 by FiercePharma
FDA approves Vertex Pharmaceutical's Casgevy and Bluebird Bio's Lyfgenia, the first cell-based gene therapies for sickle cell disease in patients 12 years and older; both treatments use patients' own blood stem cells, a major advantage in gene therapy
Published: December 08, 2023 by U.S. Food and Drug Administration (FDA)

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count